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IN SILICO ASSESSMENT OF BIOMEDICAL PRODUCTS: THE 
CONUNDRUM OF RARE BUT NOT SO RARE EVENTS IN TWO CASE 
STUDIES 
ABSTRACT  
In silico clinical trials, defined as ÒThe use of individualised computer simulation in the 
development or regulatory evaluation of a medicinal product, medical device, or medical 
interventionÓ, have been proposed as a possible strategy to reduce the regulatory costs of 
innovation and the time to market for biomedical products.  We review some of the the literature 
on this topic, focusing in particular on those applications where the current practice is 
recognised as inadequate, as for example the detection of unexpected severe adverse events too 
rare to be detected in a clinical trial, but still likely enough to be of concern.  We then describe 
with more details two case studies, two successful applications of in silico clinical trial 
approaches, one relative to the Padova Ð UVA simulator that the FDA has accepted as possible 
replacement for animal testing in the pre-clinical assessment of artificial pancreas technologies, 
and the second an investigation of the probability of cardiac lead fracture, where a Bayesian 
network was used to combine in vivo and in silico observations, suggesting a whole new 
strategy of in silico-augmented clinical trials, to be used to increase the numerosity where 
recruitment is impossible, or to explore patientsÕ phenotypes that are unlikely to appear in the 
trial cohort, but are still frequent enough to be of concern. 
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INTRODUCTION  
Computer modelling and simulation can be used in many ways to support product development, 
including the activities associated to the assessment of efficacy and safety (sometime referred 
as Òde-riskingÓ) within their context of use: this term refers to the actual conditions under which 
a given product is or will be used.  Hereinafter is used to indicate the use case scenarios for 
which safety and/or efficacy have been assessed. In the case of biomedical products these 
assessment activities are codified in regulatory evaluation frameworks, which are surveilled by 
agencies such as the Food and Drug Administration (FDA) in USA.  Here we focus our attention 
on the so so-called In Silico Clinical Trials (ISCT), defined as ÒThe use of individualized 
computer simulation in the development or regulatory evaluation of a medicinal product, 
medical device, or medical interventionÓ 1. The keyword is ÒindividualizedÓ.  The idea is to 
recreate the concept of in vivo trial using an in silico approach, where a large number of 
individual patients is modelled by initializing a disease/intervention model with quantitative 
information either measured on an individual (subject-specific model), or sampled from 
population distributions of those values (population-specific model). 
A 2014 report of the Tufts Center for the Study of Drug Development, USA suggests that the 
cost to bring to the market a new pharmaceutical product has been increasing exponentially in 
the last decades, reaching the $2.5bn 2.  Of these $1.5bn are due the clinical assessment, the so-
called clinical trials.  This poses a tremendous barrier to innovation, and makes more difficult 
to meet at reasonable prices the clinical needs posed by rarer conditions.  In almost every other 
  
industrial sector where the cost of de-risking for mission-critical products is an issue, virtual 
prototyping has become the best solution; but for biomedical products the use of computer 
modelling and simulation is still somehow limited.  According to the recently published 
Avicenna Roadmap 1, there are three major barriers: i) cultural resistance from the content 
experts - mostly biologists, pharmacologists, and medics with limited background in 
mathematics and physics; ii) resistance of the regulators, who historically did not accept 
evidences obtained in silico for the certification process of new biomedical products, especially 
those in higher risk categories; and iii) the inherent complexity associated with the accurate 
quantitative modelling of living organisms. There are signals that this situation is changing, 
albeit not as quickly as it could.   
The cultural barriers play an important role.  The pharmaceutical industry is using more and 
more bioinformatics and molecular systems biology in the discovery phase, following the 
trends in molecular biology research 3, 4.  Because this area employs mostly biochemists, who 
have much greater familiarity with simulation technologies, there is substantial use of molecular 
dynamics simulation to define the mechanism of action of a new compound (i.e. 5). And there 
is an extensive use of population pharmacokinetics and pharmacodynamics modelling (i.e. 6), 
because it is based on a phenomenological statistical modelling reasoning that is familiar to 
clinical researchers. But the adoption of subject-specific modelling involving mechanistic, 
multiscale, physiology-based approach is still quite limited. Thus, it should not be a surprise if 
the medical device industry, where the R&D staff has more frequently an engineering and 
physical sciences background, is moving much faster in this direction. 
After years of rejection, some regulators are now beginning to consider a possible role for 
computer modelling and simulation in the certification process for biomedical products.  The 
United States Food and Drug Administration (US-FDA) is leading this trend, worldwide.  In 
January 2014 they produced a draft guidance for FDA staff and industry on ÒReporting of 
Computational Modeling Studies in Medical Device SubmissionsÓ 1 .  In parallel they 
contributed to the establishment of an ASME Standardisation Committee V&V-40 
ÒVerification and validation in computational modeling of medical devicesÓ 7. Additionally, 
FDA participated in formation of the Medical Device Innovation Consortium (MDIC) in 2012. 
The MDIC is a public-private partnership created with the sole objective of advancing medical 
device regulatory science, and has sponsored a working group focused on incorporating 
engineering data into clinical studies with a virtual patient framework 8. The recently approved 
US Congress bill stating Òurges FDA to engage with device and drug sponsors to explore greater 
use, where appropriate, of In Silico trials for advancing new devices and drug therapy 
applicationsÓ 9.  Only a few days later the European Parliament recommended the European 
Medicine Agency to ÒÉ develop a framework for the regulatory acceptance of alternative 
models and shall take into consideration the opportunities presented by these new concepts 
which aim at providing for more predictive medicines. These concepts may be based on human 
relevant computer or cellular models, pathways of toxicity, or adverse outcome pathwaysÓ 10. 
Of course all this is driven by the growing capability of simulation technologies to accurately 
simulate complex physiological processes, such as the progression of a disease, the effect of 
interventions on such progression, and in some cases the manifestation of side effects and 
complications due to these interventions.  This relies on significant pre-competitive research 
investments done in the last 10 years in the area of physiological modelling. Large scale 
research initiatives such as the Virtual Physiological Human 11 funded by the European 
Commission, or the portfolio of grants coordinated through the USA Interagency Modeling and 
                                                
1 http://www.fda.gov/RegulatoryInformation/Guidances/ucm371016.htm  
  
Analysis Group (IMAG) 12have driven a robust development of in silico technologies, in 
particular those capable of modelling individual subjects, that are particularly relevant here.  
Some of these resources were used to develop modelling standards, aimed to simplify the 
exchange of models between researchers and users. The first of such modelling standards was 
CellML 13, 14, a mark-up language designed to handle any type of biophysical model.  Another 
standard called FieldML is used to describe spatially varying structure and processes 15, 16. 
The heart was one of the first targets of VPH researchers.  From the seminal works linked to 
the Cardiome Project 17-19, researchers progressively focused more and more on clinical targets 
such treatment stratification for coronary stenosis patients 20, 21, better planning of cardiac re-
synchronisation therapy 22, 23, or the personalisation of transcatheter valve implantation 
procedures 24, 25. The FDA-approved HeartFlow service, using a patient-specific model 
generated from coronary computed tomographic angiography images, can predict the value of 
the FFR without any invasive procedure 26. A similar application makes it possible to perform 
an accurate differential diagnosis of pulmonary hypertension 27. Some notable results were 
obtained for abdominal aortic aneurysms 28. 
Some applications for musculoskeletal pathologies are quite mature.  Subject-specific models 
proposed to predict the risk of bone fracture in osteoporotic patients 29-31 achieved clinical 
accuracy of 75-85% 32, 33. Whole body patient-specific models are also used in the treatment 
planning and functional grading of pediatric cerebral palsy patients 34-41, and in the analysis of 
the neuromuscular control. An interesting derivation of this research line is the stochastic 
modelling of neuromuscular control 42-44. 
Multiscale approaches were used to investigate the role that molecular constituents in the 
macroscopic mechanical properties of tendons 45-48, bone 29, 49-52, muscles 46, 53-56, etc. Other 
interesting work has been done on the ethiopathogenesis of osteoarthritis 57, osteogenesis 
imperfecta 58, the biomechanics of parturition 59, 60, and on the response for individual patients 
with breast cancer undergoing neo-adjuvant therapy 61. 
The general approach to establishment of credibility for in silico clinical trials revolves around 
the assumption that in vivo studies, whether on animals or on humans are the most reliable 
source of information, and any in silico approach should be ÒvalidatedÓ against them.  Thus, in 
the clinical assessment of subject-specific models, a group of patients is examined to collect 
quantitative information required to initialize the model, which is then used to predict one or 
more outcome biomarkers for each patient.  The same outcome biomarkers are then observed 
experimentally, whether using an invasive technique or after enough time to make the direct 
experimental observation possible.  For example, virtual Fractional Flow Reserve (vFFR) 
models, aimed to replace the direct invasive measurement of FFR with endovascular pressure 
probes, are validated against such measurements 21.  Models that predict the growth of solid 
tumors when treated with a specific chemotherapy are instead validated against the tumor size 
as measured through medical imaging, after the chemotherapy cycle has been completed 61. 
All this is based on the assumption that in vivo clinical trials work fine, and the motivation for 
replacing them is related to the risk, duration or cost that the trial involves, but not to their 
ability to provide a reliable answer on the safety and/or efficacy of a new biomedical product. 
Unfortunately, this is not always the case. Below we present two real-world cases, both 
presenting success stories for ISCT, where the prime mover of the development were the 
shortcomings of the current in vivo trials.  The problem is the numerosity (intended as the 
number of patients enrolled in the trial), or better its relation with the level of acceptable risk.  
A medical device in risk class III is typically tested in phase II clinical trials of over 100 patients.  
Trivializing the problem a bit, this leaves us with a 1% probability that something really wrong 
  
could happen with our new device, but the clinical trials would not observe it.  In practice the 
problem is more complex because any outcome depends on multiple factors, and it is the 
combination of infrequent unfavorable conditions that produces an adverse effect.  While the 
probability of these adverse effects may be low, even a small percentage can be unacceptable 
if the effect is very serious. In these cases, in silico clinical trials can play an important role as 
the two following examples demonstrate. 
 
THE PADOVA / UVA SIMULATOR  
Two Nature reviews written a decade apart point to the rapidly increasing global prevalence of 
diabetes mellitus as a result of population ageing, urbanization and associated lifestyle changes 
62, 63. Between 1980 and 2010, the number of people with diabetes mellitus worldwide has more 
than doubled 64.  In 2010, an estimated 285 million people worldwide had diabetes mellitus, 
90% of whom had type 2 diabetes (T2DM) and the rest had type 1 diabetes (T1DM). This 
number is projected to rise to 439 million by 2030 65. On March 6, 2013, the American Diabetes 
Association released data showing that the total costs of diagnosed diabetes in the U.S. have 
risen to $245 billion in 2012 from $174 billion in 2007, a 41 percent increase over five years. 
Hospital impatient days and emergency care account for 43 percent of this cost 66. The only 
proven treatment of diabetes is the active maintenance of blood sugar levels within a target 
range 67, 68. Thus, diabetes is a prime example of an enormous health care problem the only 
solution of which is integration of advanced technologies aiming personalized precise 
treatment, synergistic drug-device integration and, eventually, functional replacement of the 
failing beta cell.  
In silico experiments are of enormous value to accelerating diabetes technology development 
and drug design. It is often not possible, appropriate, convenient, or desirable to perform an 
experiment on human subjects because it cannot be done at all, or it is too difficult, too 
dangerous, or unethical. In such cases, simulation offers an alternative way of experimenting 
in silico with the system. Several simulation models have been published since the 1960Õs, 
mostly in biomedical engineering journals 69-75, but their impact in the field has been modest. 
The reason is that all of these models were average models and, as a result, their capabilities 
were generally limited to predicting a population average that would be observed during a 
clinical trial. However, given the large observed inter-individual variability, an average model 
approach cannot describe realistically the variety of individual responses to diabetes treatment. 
Thus, to enable realistic in silico experimentation, it is necessary to have a diabetes simulator 
equipped with a cohort of in silico ÒsubjectsÓ that spans sufficiently well the observed inter-
individual variability of key metabolic parameters in the general population of people with type 
1 and type 2 diabetes. 
 
A Serendipitous Beginning 
The story of the FDA accepted UVA/Padova Type 1 simulator began largely by chance. In 
2006 as part of a NIH program project studying the effects of two-year administration of Òyouth 
pillsÓ in elderly men and women, physiological performance, body composition, and bone 
density were measured in 204 nondiabetic individuals 76. These subjects underwent a triple 
tracer meal protocol which provided, in addition to plasma glucose and insulin concentrations, 
model-independent estimates of fundamental fluxes of the glucose system, including the rate 
of appearance in plasma of ingested carbohydrates, endogenous glucose production, glucose 
utilization and insulin secretion 77. This rich flux & concentration portrait was key to developing 
a large-scale glucose-insulin model, which was impossible to build from only plasma glucose 
  
and insulin concentrations. A model including 18 differential equations with 42 parameters, 33 
of which were free and 9 were derived from steady-state constraints, was identified in each 
individual by using a Bayesian forcing function strategy 78, 79. From the model parameter 
estimates of the 204 subjects participating in this study, the inter-individual variability was 
described in a nondiabetic population. From there, using the joint multivariate probability 
distribution of the model parameters, any number of virtual subjects could be generated by 
random sampling, thereby producing a virtual ÒpopulationÓ. 
Simultaneously with the events above, and thanks to the advent of minimally-invasive 
subcutaneous (s.c.) continuous glucose sensors (CGS), increasing academic, industrial, and 
political effort has been focused on the development of a s.c.-s.c. closed-loop control systems 
for diabetes, which became known as the Artificial Pancreas (AP). Generally, the AP uses a 
CGS coupled with a s.c. insulin infusion pump, and a control algorithm directing insulin dosing 
in real time.  
 
Accelerating Artificial Pancreas Research: the FDA accepted Type 1 Diabetes Simulator  
In September 2006, the Juvenile Diabetes Research Foundation (JDRF) initiated the Artificial 
Pancreas Project and funded a consortium of university centers in the US and Europe to carry 
closed-loop control research. At the time, the regulatory agencies mandated demonstration of 
the safety and feasibility of AP systems in animals, e.g. dogs or pigs, before any testing could 
begin in humans. This approach was reported in two papers showing the use of the Medtronic 
AP system first in 8 dogs 80 and then, later, in 10 people 81. However, it also became evident 
that animal studies were slow and cumbersome, and that a simulator of T1DM would allow a 
cost-effective preclinical testing of AP control strategies by providing direction for subsequent 
clinical research and ruling out of ineffective control scenarios. We argued that a reliable large-
scale simulator would account better for inter-subject variability than small-size animal trials, 
and would allow for fast and extensive testing of the limits and robustness of AP control 
algorithms. 
We therefore set to build a simulation environment based on the data and the expertise 
accumulated at the University of Padova and the University of Virginia Ð two groups that were 
already collaborating on several aspects of diabetes technology. A first necessary modification 
of the existing models 79 was the substitution of endogenous insulin secretion subsystem with 
an exogenous s.c. insulin delivery, i.e. an insulin pump. This required describing insulin 
absorption with a two-compartment model approximating non-monomeric and monomeric 
insulin fractions in the s.c. space. Given the absence in 2006 of tracer studies in T1DM similar 
to those described above for healthy subjects, a more difficult task was the description of inter-
person variability. In order to obtain the joint model parameter distributions in T1DM we 
introduced certain clinically relevant modifications to the models developed in health.  The 
resulting T1DM simulation model included 13 differential equations and 35 parameters, 26 of 
which were free and 9 were derived from steady-state constraints (Figure 1). Once the T1DM 
model was built, its validity was tested using number of T1DM data sets including adults, 
adolescents, and children. Now the Padova-UVA simulator is equipped with 300 virtual 
ÒsubjectsÓ: 100 adults, 100 adolescents, and 100 children, spanning the variability of the T1DM 
population observed in vivo. In addition, the simulator is equipped with models of CGS and 
insulin pumps. With this technology, any meal and insulin delivery scenario can be tested 
efficiently in silico, prior to its clinical application (Figure 2) 82. 
After extensive testing, in January 2008, this simulator was accepted by the U.S. Food and Drug 
Administration (FDA) as a substitute to animal trials for the preclinical testing of control 
  
strategies in artificial pancreas studies and has been adopted by the JDRF AP Consortium as a 
primary test bed for new closed-loop control algorithms. The simulator was immediately put to 
its intended use with the in silico testing of a new model predictive controller, and in April 2008 
an investigational device exemption (IDE) was granted by the FDA for a closed-loop control 
clinical trial. This IDE was issued solely on the basis of in silico testing of the safety and 
efficacy of AP control algorithm, an event that set a precedent for future clinical studies 83. In 
brief, to test the validity of the computer simulation environment independently from the data 
used for its development, a number of experiments were conducted, aiming to assess the model 
capability to reflect the variety of clinical situations as closely as possible. These experiments 
included: 
A. Reproducing the distribution of insulin correction factors in the T1DM population of 
children and adults, which tests that the variability in the action of insulin administered by 
control algorithms will reflect the variability in observed insulin action; 
B. Reproducing glucose traces in children with T1DM observed in clinical trials performed 
by the Diabetes Research in Children Network (DirecNet) consortium; 
C. Reproducing glucose traces of induced moderate hypoglycemia observed in adults in 
clinical trials at the University of Virginia, which provides comprehensive evaluation of 
control algorithms during hypoglycemia. 
Thus, the following paradigm has emerged: 1) in silico modelling could produce credible 
preclinical results that could substitute certain animal trials and 2) in silico testing yields these 
results in a fraction of the time and the cost required for animal trials. This was a paradigm 
change in the field of T1DM research: for the first time a computer model has been accepted 
by a regulatory agency as a substitute of animal trials in the testing of insulin treatments. Since 
its introduction, this simulator enabled an important acceleration of AP studies, with a number 
of regulatory approvals obtained using in silico testing. A total of 140 candidate control 
algorithms have been formally evaluated from March 2008 to August 2014: 4 in 2008, 86 in 
2009, 32 in 2010, 2 in 2011, 6 in 2012, 3 in 2103, and 7 in 2014. These 140 evaluations 
represented 16 AP projects, which typically resulted in IDEs being submitted to FDA after final 
algorithm validation. However, one needs to emphasize that good in silico performance of a 
control algorithm does not guarantee in vivo performance; it only helps to test the stability of 
the algorithm in extreme situations and to rule out inefficient scenarios. Thus, computer 
simulation is only a prerequisite to, but not a substitute for, clinical trials. 
 
Further Developments of the Padova-UVA Type 1 Diabetes Simulator 
Since 2012, the AP studies successfully moved to outpatient free-living environment and 
became longer, with durations of up to several weeks 84-87. These trials are collecting large 
amounts of data, typically including closed-loop control and an open-loop mode as a 
comparator. New data became available on hypoglycemia and counter-regulation as well, 
which allowed an update of the in silico model in the 2014 88. This new version has been proven 
to be valid on single-meal scenarios: in fact, it has been shown that the simulator was capable 
of well describing glucose variability observed in 24 type 1 diabetes subjects who received 
dinner and breakfast in two occasions (open- and closed-loop), for a total of 96 postprandial 
glucose profiles 89. The simulator domain of validity was then extended by the introduction of 
diurnal patterns of insulin sensitivity based on data in 19 T1DM subjects who underwent a 
triple-tracer study 90. This has allowed the incorporation of a circadian time-varying insulin 
sensitivity into the simulator, thus making this technology suitable for running multipleÐmeal 
scenarios and enabling a more robust design of AP control algorithms 91.  
  
Finally, another validation of the simulator was done by comparing in silico output to data of 
47 T1DM subjects from 6 clinical centers, who underwent three randomized 23-hour 
admissions, one open-loop and two closed-loop. The protocol approximated real life with 
breakfast, lunch and dinner and collected 141 daily traces of glucose and insulin concentrations. 
We used Maximum a Posteriori Bayesian approach, which exploited both the information 
provided by the experimental data and the a priori knowledge on model parameters represented 
by the joint parameter distribution incorporated in the simulator. Plasma insulin concentrations 
were used as model-forcing functions, i.e. assumed to be known without error. The 
identification of the simulator on a specific person provided an in silico ÒcloneÓ of this person; 
thus, the possibility emerged to clone a large number of T1DM individuals and to move from 
single-meal to breakfast/lunch/dinner scenario, thus accounting for intra-subject variation in 
glucose absorption and insulin sensitivity 92 . These enhanced versions of the T1DM simulator 
have been, and still are, extensively used in designing and testing the new generation of closed-
loop control algorithms, in particular those aiming at individualization, i.e. tuning the control 
algorithm to a specific person 93, and those making the AP adaptive, i.e. learning from the 
behavior in time of a specific person 94.  
 
The Type 1 Diabetes Simulator: New Applications 
The Padova-UVA simulator has been used in a variety of contexts by 32 research groups in 
academia, by companies active in the field of diabetes pharma and technology and has led to 
63 publications in peer reviewed journals (data updated to 2013). Here we briefly discuss the 
use of the simulator in two important diabetes technology areas, CGS and inhaled insulin. 
 
Glucose sensors 
In the past 10 years, the accuracy of s.c. glucose sensing has moved from MARD (Mean 
Absolute Relative Difference, a common metric used to compare CGS to reference blood 
glucose) of 19.7 % of the Medtronic RT-Guardian to a 9% of the Dexcom G4 Platinum (with 
software 505). Does this improved accuracy make s.c. glucose sensors reliable for insulin 
treatment decisions in place of self-monitoring of blood glucose? A clinical trial addressing this 
question would be almost impossible since the required number of patients to ensure 
exploration of the tail of the sensor MARD distribution would be huge. Also, retrospective data 
are not too useful because it is impossible to see what would have happened of the insulin 
dosing was based on CGS rather than self-monitored blood glucose. Determining if CGS is safe 
and effective enough to substitute self-monitoring of blood glucose in diabetes management 
has therefore become a hot topic of investigation for the diabetes research community and 
regulatory agencies. Computer simulation is of critical importance because it allows to perform 
in silico clinical trials (see also the outcome of a recent FDA panel meeting 95 and commentary 
96. The simulator used in this case is in the context of a patient decision-making model (Figure 
3). By describing the blocks B, C and D and defining in silico scenarios to recreate real-life 
conditions, e.g. 100 adults and 100 paediatric patients, 3 meals per day with variability in time 
& amount and meal bolus behaviour, we have evaluated standard outcome metrics, e.g. time in 
severe hypo, time in hypo, time in target, hypo- or hyperglycemic events, for both CGS and 
self-monitored blood glucose scenarios. Our preliminary results based on 40,000 simulated 
virtual subjects in adults support the non-inferiority of CGS vs. self-monitored blood glucose; 
moreover, time below 50 mg/dl and time below 70 mg/dl are significantly improved, time 
between 70 and 180 mg/dl and time above 180 mg/dl are slightly improved, and the number, 
extent, and duration of hypoglycemic events are significantly reduced 97. 
  
 
Inhaled insulin 
The delayed onset of action inherent to the current s.c. injected insulin analogues makes their 
optimal administration difficult, particularly in the presence of real-life perturbations, such as 
meals. Inhaled prandial insulin with rapid kinetics may overcome some of these delay, but also 
introduces new challenges. Technosphere¨ insulin (TI) (MannKind Corporation, Valencia, 
CA) is a dry powder formulation of recombinant human insulin adsorbed onto Technosphere 
microparticles 98. Upon inhalation, these microparticles can reach the deep lung allowing 
absorption into the systemic circulation with a time to maximum serum insulin concentration 
of 12Ð15 min 99. In a phase III trial in T1DM, TI demonstrated non-inferiority to s.c. prandial 
insulin Aspart (Novolog¨) 100. However, because of the fast onset and short duration of action, 
the dosing regimen of TI in this study may have been suboptimal. Designing a clinical trial to 
identify the optimal dosing regimen and the optimal titration rule would be prohibitively 
expensive because countless combinations would need to be tested. Thus, we performed in 
silico trials translating the known pharmacokinetic profile of TI (and insulin Lispro as 
comparator) into the expected post-prandial glucose response following a meal tolerance test 
101. The simulations suggested that post-meal dosing (at 15 or 30 min after start of the meal) 
and split dosing (with 15 or 30 min split times) results in a flatter post-prandial glucose profile 
than at-meal dosing (Figure 4). In several virtual patients the flatter profile allowed for a higher 
TI dose without increasing the risk for hypoglycemia events. In addition, the simulations 
revealed that the selection of the titration rule is crucial to achieve optimal treatment benefit. 
Simulated up-titrations using 20 titration rules identified that the best time to measure post-
prandial glucose is 150 min after the meal and the upper threshold for the glucose target should 
be 150 to 160 mg/dL. These optimized titration rules can considerably improve the efficacy of 
TI on post-prandial glucose control. Clinical studies are currently planned to validate the results 
from these in-silico meal test simulations. 
 
IN SILICO-AUGMENTED CLINICAL TRIAL OF DEFIBRILLATOR LEADS  
When it occurs, conductor fracture is widely recognized as a failure mode that can have serious 
implications 102. Recent advances in test methods, numerical simulation, and in-vivo imaging 
have enabled more thorough methods of cardiac lead fracture analysis 103, 104. A Bayesian 
Network methodology has been developed that integrates in-vivo measurements of device 
loading with in-vitro measurements of fatigue strength to simulate fatigue lifetime 105. Many 
plausible combinations can be simulated within this framework to generate a family of fatigue 
fracture survival curves, enabling sensitivity analyses and the construction of confidence 
bounds on survival.  
Since the fracture model predicts the same endpoint that would be observed in clinical practice 
with the same population variability, we use the term virtual patients to refer to these 
simulations.  
The methodology is given below and in 105: 
1. Measure representative use condition and lead fatigue strength to inform estimates 
for population statistics 
2. Estimate posterior parameter distributions for inputs 
3. Randomly generate use conditions  
4. Randomly generate fatigue strength   
5. Calculate time to fracture and survival curve   
  
6. Repeat from step 2 to simulate multiple virtual patient cohorts  
A Bayesian framework was utilized to estimate all of the parameters for the distributions used 
in the simulation. This approach accounts for uncertainty due to sampling. For example, small 
sample sizes result in large uncertainty, which is reflected in high variability between virtual 
patient cohorts.  
This approach was developed for fatigue of conductors within cardiac leads, specifically for 
conductor coils.  Coil fatigue is governed by the magnitudes and frequency of bending cycles.  
Previous work 106 has shown that curvature of a coil is related to stress and strain, so we adopt 
curvature as a fatigue stressor variable.  When coupled with the highly mobile anatomical 
structures around the shoulder, cardiac leads can encounter potentially large amplitudes of 
bending.  Both curvature and frequency are statistical in nature, reflecting variability between 
implanted shapes and patient activity.  To account for the wide span of patient age and 
associated activity level, we adjust the cycle count distributions according to the patient 
demographics.   
With input parameters for cycle counts, curvature amplitude and fatigue strength, a Monte Carlo 
simulation can be performed to simulate many possible fatigue experiences, generating a 
survival curve.  Repeating the process with a new set of parameter estimates enables the 
generation of a family of predicted survival curves, which can be used to generate confidence 
bounds, reflecting uncertainty in the input data.   
The virtual patients can be implemented as prior knowledge in a Bayesian clinical trial. The 
statistical framework leverages FDA guidance for the use of Bayesian statistics in medical 
device clinical trials 104.  This approach can have benefits of decreased sample size and trial 
length while minimizing impact to study endpoints, type I error, and type II error. The methods 
described here are currently being evaluated in a mock IDE submission as part of a collaborative 
FDA-industry working group within the Medical Device Innovation Consortium (MDIC).    
There are two elements that may be novel to the statistician implementing or reviewing this 
method, discussed briefly below.   
1. Many cohorts of virtual patient outcomes will be incorporated via a modified version of 
the power prior method. Cohort differences represent model uncertainty. 
2. The number of virtual patients will be controlled by a loss function, which bases the 
number of virtual patients on the agreement between real and simulated data. 
Incorporation of each cohort of virtual patient data is based on the method of power priors 107.  
In this method, a discount value between 0 and 1 is applied to prior data, where 0 indicates no 
borrowed information and 1 indicates full borrowing. Unlike historical data, there is not a finite 
limitation on the number of virtual patients that can be simulated. Therefore, in order to better 
express variability, it is desirable to simulate a large number.  However, the number of virtual 
patients incorporated into the study is subject to constraints driven by desired power and type I 
error.  The modification developed by the working group converts the potentially large number 
of virtual patients to an effective number for incorporating into the study data. With this 
approach, the number of simulated patients can be kept large enough to capture the tails of the 
distribution, and will be down-weighted to a level that does not overwhelm the clinical data, 
thereby protecting against a type I error. Integration across the multiple virtual patient cohorts 
accounts for engineering model uncertainty.  
A loss function controls the number of virtual patients incorporated into the study data. This 
approach utilizes a function that scales the virtual patient number based on the agreement with 
the study data.  In the approach developed by the working group, a Weibull cumulative 
  
distribution function is constructed that uses a Bayesian p-value as an input.  When the clinical 
and virtual data are highly similar, the p-value approaches 1 and the full amount of virtual 
patients can be incorporated. Likewise, when the clinical data diverges from the virtual data, 
the p-value approaches zero and the number of virtual patients also approaches zero.  The 
Weibull parameters control the relationship between p-value and fraction of virtual patients 
allowed. The loss function parameters and the maximum number of virtual patients allowed in 
the study are items to be agreed upon prior to starting the study.  
There are two ways in which this method is suitable for a Bayesian adaptive design with interim 
looks.  First is the traditional case where we adapt the trial based on the clinical endpoint 
response variable. Second, we adapt the trial based on input data used in the engineering model, 
collected from the (real) enrolled patients. Both cases can be used for sample size re-estimation 
or stopping the trial early for success or futility. 
The mock IDE submission process is a novel means of demonstrating the statistical methods 
and considerations associated with using this framework for a clinical trial designed with virtual 
patients. The activity started in 2014, sponsored by MDIC, and is expected to complete in mid-
2016. Two pre-submission meetings were held at FDA in 2015 to introduce the concept and 
discuss the virtual patient model. A final pre-submission meeting is planned for 2016 to discuss 
the clinical statistical methods. Updates from the work have been given in conference 
presentations, and a complete review of the method and mock submission process will be given 
in a future FDA workshop. 
 
DISCUSSION  
Although very different, these two examples illustrate the concept of using subject-specific 
computer simulations to generate ÒVirtual PatientsÓ that can replace animal experimentation, 
or supplement human clinical trials. 
With respect to replacement of animal experimentation, it is important to acknowledge that in 
the context of product de-risking, animal models are based on organisms different, sometimes 
significantly different, from humans. In addition to differences in biology, anatomy, and 
physiology between the selected animal model and humans, it is typically necessary to develop 
a disease model, by intervening on the animal in various ways (genetic manipulation, surgery, 
environmental control, exposure to exogenous agents such as viruses or bacteria, etc.).  In the 
end the Òreality distanceÓ between an ovariectomized mouse and a post-menopausal woman 
may be as large as the difference between the same woman and a computer model of bone 
remodeling based on data of individual patients.  Simply because it involves a living organism, 
the animal model is not necessarily Òmore realÓ.  Like with any other model, we need to 
compare to what extent each model accurately predicts the effect the product being tested will 
produce in humans, regardless of whether the model is in vivo, in vitro, or in silico. 
In many cases, it is difficult if not impossible to conclusively demonstrate the accuracy of a 
pre-clinical model (again whether based on in vivo, in vitro, or in silico methods); in these 
cases, it is important to acknowledge the role that patients organizations, such as the JDRF in 
the case of the Padova-UVA Type 1 Diabetes Simulator, can play in representing in a fully 
unbiased way, the balance between the need for surveillance and that for innovation.  While, in 
principle, the regulators are also supposed to represent both sides of this equation, in practice 
in most countries regulators are put under pressure by the public opinion if an authorized 
product fails, and are under much less pressure if innovation is slow.  PatientÕs organizations 
can thus play a vital role in the regard. 
  
The second project we presented pioneers the use of subject-specific models in the clinical 
assessment of medical devices.  There are essentially three groups of motivations that drive this 
type of exploration.  The first is to overcome limitations associated to specific products/diseases 
where a reliable clinical assessment is impossible.  The most obvious example is the testing of 
products to treat rare diseases, where the difficulty is enrolling enough patients to achieve 
statistical power. 
The second is linked to the need to test for a rare but severe failure scenario in a class of products 
that are normally trialed clinically with a cohort size that makes very unlikely to observe that 
failure mode.  The most common scenario is that produced by the interaction of multiple factors, 
when each can assume a fairly unlikely value, for example a patient who is severely overweight, 
and conducts a very active lifestyle.   
The third group of motivations is related to the cost and duration of clinical trials. While the 
cost of innovation in the biomedical industry has reached levels that concern most analysts and 
pose a serious threat to the long-term sustainability of universal healthcare systems, it is 
unquestionable that the idea of replacing, even only partially, a clinical trial with a computer 
simulation, would raise many eyebrows.  Thus, we recommend to begin using in silico clinical 
trials for evaluation of technologies targeting rare conditions, where no viable statistically 
significant trial design is possible, and to test the occurrence of rare failure scenarios. 
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Figure 1: Scheme of the glucose metabolism model included in the FDA-
accepted T1DM simulator 82,88.  
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Figure 2: Three uses of the T1DM simulator. 
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Figure 3: The T1DM patient decision-making model 96. 
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Figure 4: Glucose time courses obtained by simulating meal test in 100 
virtual subjects receiving an individualized at-meal dose of TI selected by 
titration rule based on PPG90<160mg/dL condition (A), or an 
individualized at-meal dose of TI selected by titration rule based on 
PPG150<160mg/dL condition (B), or an individualized post-meal dose 
(Dt=15 min) of TI selected by titration rule based on PPG150<150mg/dL 
condition (C), or an individualized split dose (Dt=15 min) of TI selected by 
titration rule based on PPG150<150mg/dL condition (D). A comparison of 
the mean glucose profiles for at-meal targeting PPG90<160 mg/dL (blue), 
for at-meal dosing targeting PPG150<160 mg/dL (red), post-meal dosing 
targeting PPG150<150 mg/dL (green) and split dosing targeting 
PPG150<150 mg/dL (magenta) is shown in (E) 92. 
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